PME is in surprising demand considering the blood bath elsewhere in the market, albeit PME's rise is not on large volume
.
What half year EPS are we expecting and what would constitute a disappointment?
As of 24 Nov 2019, Gold in Sacks are forecasting FY2020 revenue of $59.1m versus the prior of $50.1m and EPS of 22.5c (diluted) versus the FY2019 statutory EPS of 18.3c
(PME reported 22c ”underlying” for 2019).
Morningstar is forecasting FY2020 EPS of 22.4c.
I don’t know if that comes from Morningstar’s quantitative robot or a warm-blooded computer.
The 2019 HY reported statutory EPS was 8.7c.
The PME update on 16 Dec flagged a weighting towards the second half.
But, is that modified in absolute terms by the preceding remarks that the results so far, are already “comfortably ahead” of their budget, which was predicated on “strong organic growth”?
My guess is that the market expectation for H1 2020 ought to be around 10.3c (equivalent to NPAT of $10.7m).
I think 12 cents or better would be seen as a beat.
Cheers
(20min delay)